Therapeutics Acquisition Corp.

If you purchased Therapeutics Acquisition Corp. securities and would like to join the action, please click "Join This Action" below.

RACA MERGER INVESTIGATION: HALPER SADEH LLP ANNOUNCES INVESTIGATION INTO WHETHER THE MERGER OF THERAPEUTICS ACQUISITION CORP. IS FAIR TO SHAREHOLDERS; INVESTORS ARE ENCOURAGED TO CONTACT THE FIRM – RACA

April 28, 2021.

New York, New York—Halper Sadeh LLP, a global investor rights law firm, is investigating whether the merger of Therapeutics Acquisition Corp. d/b/a Research Alliance Corp. I (NASDAQ: RACA) and POINT Biopharma Inc. is fair to Therapeutics Acquisition shareholders.

The investigation concerns whether Therapeutics Acquisition and its board of directors violated the federal securities laws and/or breached their fiduciary duties to shareholders by failing to, among other things: (1) obtain the best possible consideration for Therapeutics Acquisition shareholders; and (2) disclose all material information necessary for Therapeutics Acquisition shareholders to adequately assess and value the merger consideration. On behalf of Therapeutics Acquisition shareholders, Halper Sadeh LLP may seek increased consideration for shareholders, additional disclosures and information concerning the proposed transaction, or other relief and benefits.

Halper Sadeh LLP represents investors all over the world who have fallen victim to securities fraud and corporate misconduct. Our attorneys have been instrumental in implementing corporate reforms and recovering millions of dollars on behalf of defrauded investors.

Attorney Advertising. Prior results do not guarantee a similar outcome.

Certification

Scroll to Top